Asthma, Mild Asthma
Conditions
Keywords
Salbutamol, Propellant HFA-152a, Propellant HFA-134a, Metered dose inhalers, Mild asthma
Brief summary
The primary objectives of the study are: Part 1: to characterize the potency and variability of dose response on efficacy (Provocative concentration of methacholine causing at least a 20% fall in forced expiratory volume (FEV1) \[PC20\]) of salbutamol administered via MDI with salbutamol HFA-134a or salbutamol HFA-152a in participants with mild asthma. Part 2: to compare the comparative dose response on efficacy (PC20) of salbutamol when administered via MDI with salbutamol HFA-134a or salbutamol HFA-152a in participants with mild asthma.
Interventions
A single 100, 200 or 400 μg dose, given as 1, 2 or 4 × 100 μg actuations (exvalve) at 20 second intervals.
A single 100, 200 or 400 μg dose, given as 1, 2 or 4 × 100 μg actuations (exvalve) at 20 second intervals.
DRUGPlacebo
A single placebo HFA-152a suspension or placebo HFA-134a suspension dose, given as at 20 second intervals.
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Masking description
Click here to enter text.
Intervention model description
2-part, 7-way cross- over (Part 1 and Part 2)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Male or female; females may be of childbearing potential, of nonchildbearing potential, or postmenopausal. 2. Participant must be 18 to 65 years of age inclusive, at the time of screening. 3. ≥50 kg, at the time of screening. 4. Body mass index (BMI) with 19.0-35.0 kg/m2 inclusive, at the time of screening. 4\. Documented history of asthma ≥ 6 months. 5. Receiving 1 of following asthma treatments, at a stable dose, for at least 12 weeks prior to the screening visit and is anticipated to remain stable for the duration of the study: i. Short-acting beta-agonist (SABA) only. ii. Daily maintenance low-dose inhaled corticosteroids (ICS) (defined as 100-250 μg/day fluticasone propionate or equivalent plus or minus SABA which is anticipated to remain stable for the duration of the study. iii. Daily maintenance low-dose ICS + Long-acting beta-2 agonist (LABA) therapy (low-dose ICS defined as 100-250 μg/day fluticasone propionate or equivalent as defined by GINA \[GINA, 2023\]) plus or minus SABA, which is anticipated to remain stable for the duration of the study. 6\. No severe asthma exacerbations within 6 months prior to screening and ≤1 severe exacerbation during the 12 months prior to screening. 7\. Pre-bronchodilator FEV1 ≥80% of predicted, at screening. 8. PC20 to methacholine of ≤8 mg/mL, at screening. 9. Participants should be able to withhold SABA for ≥12 hours and LABA-containing medications for ≥48 hours for the purposes of performing the spirometry and methacholine challenge at screening and during the study visits (treatment periods). 10\. A female participant is eligible to participate if she is not pregnant or breastfeeding, and Is a woman of woman of nonchildbearing potential (WONCBP) OR ii. Is a woman of child bearing potential (WOCBP) and using a contraceptive method that is highly effective. 11\. Provide signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol. 12\. Non-smokers who have not used any tobacco containing-products within 12 months prior to study start, and with a total pack year history of ≤10 pack years.
Exclusion criteria
1. Medical Conditions 1. A history of life-threatening asthma or asthma that is unstable in the opinion of the investigator. 2. A history of respiratory diseases to include (but not limited to): pneumothorax, pulmonary fibrotic disease, bronchopulmonary dysplasia, chronic bronchitis, cystic fibrosis, bronchiectasis, interstitial lung disease, emphysema, chronic obstructive pulmonary disease, tuberculosis, or other respiratory abnormalities other than asthma. 3. Asymptomatic gallstones. 4. History or current evidence of hematologic, neurologic, psychiatric, or other diseases that, in the opinion of the investigator, would put the participant at risk through study participation, or would affect the study analyses if the disease exacerbates during the study. 5. Recent eye surgery or any other condition in which raised intracranial pressure (caused by forceful exhalation) would be harmful. 6. Current use of cholinesterase inhibitor medication e.g., to treat myasthenia gravis. 2. Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day or participation in a clinical study within 30 days of study start, or 5 half-lives of study drug if that is longer. 3. Participants who are currently or in the last 15 days have worked nightshifts. 4. Regular alcohol consumption within 6 months prior to the study defined as: an average weekly intake of \>21 units for males or \>14 units for females. 5. A positive test result for drugs of abuse (including tetrahydrocannabinol) at screening or Day -1. 6. Use of combustible tobacco products, and non-combustible nicotine delivery systems, inclusive of cigarettes, cigars, pipes, and materials used to "vape" within 12 months prior to the start of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Part 1 & Part 2: Provocative concentration of methacholine causing at least a 20% fall in FEV1 (PC20) | Up to 11 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Part 1 & Part 2: Peak QTc Interval | Up to 11 weeks | — |
| Part 1 & Part 2: Peak Heart Rate (HR) | Up to 11 weeks | — |
| Part 1 & Part 2: Minimum Serum Potassium | Up to 11 weeks | — |
| Part 1: Maximum Observed Plasma Concentration (Cmax) | Up to 11 weeks | — |
| Part 1: Time to Reach Cmax (Tmax) | Up to 11 weeks | — |
| Part 1: Area Under the Plasma Concentration-time Curve up to Last Time With Concentrations Above the Lower Limit of Quantification (LLOQ) (AUC[0-last]) | Up to 11 weeks | — |
| Part 1 & Part 2: Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) | Up to 11 weeks | — |
| Part 1 & Part 2: Absolute Values for 12-lead Electrocardiogram (ECG) Recording of HR | Up to 11 weeks | — |
| Part 1 & Part 2: Absolute Values for 12-lead ECGs Recording of Intervals | Up to 11 weeks | Intervals recorded: - PR. - QRS. - QT. - QTc |
| Part 1 & Part 2: Change from Baseline for Post-dose 12-lead ECGs Recording of HR | Baseline and up to 11 weeks | The 3 predose measures will be recorded and will be averaged for HR to derive 1 baseline value. |
| Part 1 & Part 2: Change from Baseline for Post-dose 12-lead ECGs Recording of Intervals | Up to 11 weeks | The 3 predose measures will be recorded and will be averaged for QTc interval to derive 1 baseline value. Intervals recorded: - PR. - QRS. - QT. - QTc |
| Part 1 & Part 2: Number of Participants with Clinically Significant Changes in Clinical Laboratory Parameters | Up to 11 weeks | — |
| Part 1 & Part 2: Absolute Values of Vital Signs (Systolic and Diastolic Blood Pressure) | Up to 11 weeks | — |
| Part 1 & Part 2: Absolute Values of Vital Signs (Pulse Rate) | Up to 11 weeks | — |
Countries
United Kingdom
Contacts
CONTACTUS GSK Clinical Trials Call Center
CONTACTEU GSK Clinical Trials Call Center
Outcome results
None listed